Cargando…
Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
BACKGROUND: Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited. AIM: To assess the clinical characteristics of IBD patient...
Autores principales: | Rubin, Samuel J S, Balabanis, Tatiana, Gubatan, John, Habtezion, Aida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891792/ https://www.ncbi.nlm.nih.gov/pubmed/35317167 http://dx.doi.org/10.12998/wjcc.v10.i6.1787 |
Ejemplares similares
-
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
por: Weingarden, Alexa R, et al.
Publicado: (2022) -
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
por: Gubatan, John, et al.
Publicado: (2020) -
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
por: Weingarden, Alexa R, et al.
Publicado: (2021) -
1162: SINGLE-CELL IMMUNE PROFILING AND REPERTOIRE ANALYSIS OF CONVALESCENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 ANTIBODY RESPONSE
por: Gubatan, John Mark, et al.
Publicado: (2022) -
Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
por: Rubio, Marrieth G, et al.
Publicado: (2019)